RESUMEN
Objective:To explore the efficiency of Annao tablets combined with flunarizine hydrochloride capsules in the treatment of patients with vertebral basilar artery insufficiency ( VBI) . Methods:Totally 294 patients with VBI were randomly divided into group A, B and C (n=98). Group A received flunarizine hydrochloride capsules, group B received Annao tablets, group C received flunari-zine hydrochloride capsules combined with Annao tablets, and the treatment course was 15 days. The symptom scores, clinical effica-cy, blood flow velocity of vertebral-basilar artery and serum Tau level were compared among the three groups. The adverse reactions oc-curred during the treatment were recorded. Results:After the treatment, the symptom scores and clinical total effective rate of group C was (10.05 ±2.23) and 96.94%, respectively, which were better than those in the other two groups (P<0.05). After the treat-ment, the cerebral blood flow velocity, cognitive function and serum Tau level were improved in the three groups (P<0. 05), while those in group C were better than those in the other two groups (P<0. 05). No obvious adverse reaction was observed in the three groups. Conclusion:Annao tablets combined with flunarizine hydrochloride capsules is effective and safe in the treatment of patients with VBI, and the mechanism is partly related with the reduction of serum Tau protein level.
RESUMEN
Objective To study the influence of Annao tablet on the expression of transforming growth factor beta 1 (TGF-β1) in acute graft-versus-host disease (aGVHD) murine and to explore the interventional mechanism of TGF-β1 on aGVHD. Methods Hematopoietic stem cells of male Balb/c mice were transplanted to female C57BL/6 mice for the development of aGVHD murine model. Recipient mice were divided into Annao group and blank group randomly and respectively administrated with Annao soup (a kind of Chinese herb) and 0.9% sodium chloride intragastrically. Clinical symptom, survival time and body weight were recorded at 14th and 30th day and some sections of liver, small bowel and skin were taken for histological changes. Serum level of TGF-β1 were measured by enzyme-labeled immunosorbent assay (ELISA), splenocyte protein of TGF-β1 by Western Blot and TGF-β1 mRNA by fluorescent quantitation polymerase chain reaction (PCR). Results Serum level of TGF-β1 in both groups had no statistical difference (P = 0.305), but it rose to (148.31 ± 7.95) ng/mL at 14th day and (183.48 ± 5.91) ng/mL at 30th day in Annao group, which had significant difference when compared with that in blank group (P = 0.000). IOD/IODβ-actin value of TGF-β1 protein in Annao group was 0.33 ± 0.05 at 14th day and 0.56 ± 0.04 at 30th day, which was higher than that in blank group (P = 0.000) and the expression of TGF-β1 mRNA of splenocyte in Annao group was 1.24 ± 0.04 at 14th day and 2.14 ± 0.33 at 30th day which was much higher than that in blank group (P = 0.000). Conclusion Annao tablet helps to relieve symptoms of acute GVHD by raising serum level of TGF-β1 and intensifying expression of protein of TGF-β1 and its mRNA.